Entrada Therapeutics Inc.

TRDA | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.82

+$0.18 (+2.71%)

Sep 22, 2026, 12:47 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.71%

(1D)

Rating

Updated: Aug 18, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $264.56M

1D Range

6.65 6.93

52W Range

5.08 16.45

Valuation (TTM)

PE -1.67

PB 1.10

EV/EBITDA -0.51

Valuation (NTM)

Forward PE N/A

Forward PEG 0.12

Price Target $14

Cash Flow

FCF Yield -53.4%

SBC Adj. FCF Yield -62.7%

SBC Impact -17.5%

Margins

Gross Margin -754.7%

Operating Margin -3767.1%

FCF Margin -2935.9%

Growth (CAGR)

Revenue 3Y | 5Y -52.4% | 6.2%

Dil EPS 3Y | 5Y -372.6% | -10.7%

FCF 3Y | 5Y -63.2% | -71.0%

Returns

ROA -55.5%

ROE -57.6%

ROIC -62.6%

Financial Health

Net Cash

$223.01M

Current Ratio 10.89

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailmen...

Sector Healthcare

Industry Biotechnology

Employees 152

IPO Date Oct 28, 2021

Website www.entradatx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$14

Upside

+105.28%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞